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Abstract 11 
The 37kDa/67kDa laminin receptor (LRP/LR) serves various physiological and pathological 12 
roles such as enhancing tumour-related processes including metastasis, angiogenesis, cellular 13 
viability and telomerase activation in  cancerous cell lines. The present study investigates the 14 
effect of siRNA mediated downregulation of LRP/LR on pancreatic cancer (AsPC-1) and 15 
neuroblastoma (IMR-32) cells. MTT and BrdU assays revealed that siRNA mediated 16 
downregulation of LRP resulted in a significant reduction in cell viability and cell proliferation. 17 
In addition, knock-down of LRP resulted in phosphatidylserine externalisation, diminished 18 
nuclear integrity and significantly enhanced caspase-3 activity, which is indicative of apoptosis. 19 
.LRP downregulation resulted in a significant increase in caspase-8 activity in IMR-32 cells and 20 
enhanced caspase-8 and 9 activity in AsPC-1 cells. These data recommend siRNA mediated 21 
 2 
knock-down of LRP as a potential therapeutic avenue for the treatment of pancreatic cancer and 1 
neuroblastoma. 2 
Keywords 3 




Laminins are glycoproteins that play a major role in the formation of the extracellular matrix[1]. 8 
Both integrin and non-integrin laminin receptors have been identified as mediators used by 9 
laminins to carry out their functions, which include cell migration[2], adhesion[3], growth[4], cell 10 
differentiation, proliferation[5] and cell signaling[6]. One major receptor and binding partner for 11 
laminin is the 37kDa/67kDa laminin receptor precursor/high-affinity laminin receptor 12 
(LRP/LR)[7]. 13 
LRP/LR is a major extracellular matrix/non-integrin laminin receptor with high specificity and 14 
affinity for laminin-1 [8]. LRP/LR is predominantly found as a transmembrane receptor but also 15 
localizes in the cytosol[9] and the nucleus[10] – facilitating translational processes and the 16 
maintenance of nuclear structures, respectively. It plays a role in physiological processes such as 17 
cellular adhesion, migration, proliferation,  maintenance of cellular viability[11], cell cycle[12], 18 
protein synthesis[12] and processing of ribosomal RNA[13].  19 
Numerous studies have implicated LRP/LR as a key contributor to the pathogenesis of certain 20 
viral and bacterial infections [14, 15], prion-protein related diseases such as Transmissible 21 
 3 
Spongiform Encephalopathies [16], neurodegenerative diseases such as Alzheimer’s disease [17, 18], 1 
and several cancer types [19-22]. Blockage of the interaction between Laminin-1 and LRP/LR by 2 
use of the anti-LRP/LR specific antibody IgG1-iS18 has been shown to diminish levels of 3 
adhesion and invasion of various cell lines in vitro [19-25]. Therefore, it is evident that LRP/LR is 4 
crucial for metastatic processes and is a promising target for metastatic cancer therapeutics. In 5 
addition to metastasis, LRP/LR is also suggested to enhance tumour angiogenesis [26] and 6 
recently Naidoo et al. [27] and Otgaar et al. [28]elucidated a novel role for LRP/LR in mediating 7 
telomerase activity through the enhancement of hTERT activity. In particular, knock-down of 8 
LRP/LR resulted in impediment of telomerase activity in metastatic breast cancer cells, 9 
combating the pro-tumourigenic activities of LRP/LR[27]. Very recently, we showed that 10 
LRP::FLAG enhances telomerase activity concomitant with reduced senescence markers, 11 
indicating that LRP plays a profound role in the ageing process[28].  Due to the involvement of 12 
LRP/LR in these aforementioned numerous tumourigenic processes, the role of this receptor in 13 
cell survival and viability has become an attractive topic of research[29]. Recent studies showed 14 
reductions in the viability of liver (Hep3b)[30], lung (A549)[31], cervical (HeLa)[31] , breast (MCF-15 
7 and MDA-MB231)[32]  and oesophageal cancer (WHCO1)[32] cells after siRNA-mediated 16 
downregulation of LRP/LR – thus suggesting that LRP/LR plays a pivotal role in the 17 
maintenance of tumour cell viability. Furthermore it has been shown that LRP/LR plays an 18 
important role in apoptosis [30-32].  19 
Apoptosis is a process of programmed cell death necessary for the maintenance of tissue 20 
homeostasis and embryonic development [33]. Three main types of biochemical changes have 21 
been observed in apoptosis, namely caspase activation, DNA/protein breakdown, and membrane 22 
changes that result in phagocytosis [34]. There are two main pathways by which caspases can be 23 
 4 
activated and thereby induce apoptosis, namely the death receptor (extrinsic) pathway and the 1 
mitochondrial (intrinsic) pathway [34]. Recent studies made use of siRNA technology to 2 
downregulate LRP/LR and assess the effects of this down-regulation on apoptosis [31, 32]. siRNA-3 
mediated LRP/LR down-regulation was shown to significantly reduce cellular viability of lung 4 
(A549) and cervical cancer (HeLa) cells and increase the levels of caspase-3 activity in both cell 5 
lines, thus suggesting that LRP/LR is pivotal in the maintenance of cellular viability as well as 6 
the evasion of apoptosis in tumour cells. 7 
Therefore, the present study aimed to assess the role of LRP/LR on the viability and survival of 8 
highly aggressive pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells by using an 9 
siRNA approach. Additionally, both the intrinsic and extrinsic apoptotic pathways were 10 
evaluated following siRNA mediated downregulation of LRP/LR. This study showed that 11 
LRP/LR knockdown significantly reduced the viability of pancreatic cancer and neuroblastoma 12 
cells, and suggests that the observed reduction in cellular viability is due to apoptosis.  13 
 14 
Materials and Methods 15 
Cell culture. AsPC-1 and IMR-32 cells were obtained from the Fox Chase Cancer Center 16 
(USA). AsPC-1 cells were cultured in RPMI 1640 supplemented with 10% Fetal Calf Serum 17 
(FCS), 1% penicillin/streptomycin, 2mM L-glutamine, 10mM HEPES and sodium pyruvate. 18 
IMR-32 cells were cultured in Eagle Minimum Essential Medium (EMEM) supplemented with 19 
10% FCS, 1% penicillin/streptomycin, 2mM L-glutamine and 1% non-essential amino acids. 20 
Cell lines were maintained in a humidified incubator at 37ºC with 5% CO2 and were sub-cultured 21 
when 80% confluency was reached. 22 
 5 
siRNA-mediated down-regulation of LRP/LR. Cells were seeded into 6 well plates and were 1 
transfected at approximately 50-70% confluency. Transfections were performed using siRNA-2 
LAMR1 to downregulate LRP/LR and siRNA-scrambled was employed as a negative control 3 
(Dharmacon). The Dharmafect1 Transfection reagent was used according to the manufacturer’s 4 
instructions. Additionally, AsPC-1 and IMR-32 cells were transfected with Lipofectamine 3000 5 
reagent (Thermo Scientific) and either esiRNA-RPSA (targeted to LRP/LR) or esiRNA-RLUC 6 
(negative control) (Sigma-Aldrich), in order to confirm that downregulation was not due to off-7 
target effects. Thereafter, the plates were incubated at 37°C for a period of 72 hours prior to 8 
downstream experiments being performed. 9 
Western blotting. Endogenous LRP/LR levels as well as siRNA-treated LRP/LR levels were 10 
determined by employing Western blotting. In order to prepare cell lysates, cells were incubated 11 
in 500µl of lysis buffer (10mM Tris/HCl pH 7.5, 10mM EDTA, 100mM NaCl, 0.05% (w/v) 12 
deoxycholic acid (DOC), 0.5% (v/v) Nonidet-P40) for 15 minutes at 4°C. This was followed by 13 
centrifugation at 14000 rpm for 2 minutes, after which the supernatant containing the extracted 14 
proteins was retained. Cell lysates were separated on 12% SDS-PAGE gels (Bio-Rad). Proteins 15 
were transferred to PVDF membranes for 45 min at 300V and 350A. Thereafter, the membranes 16 
were blocked for 1 hour using blocking buffer (3% BSA in PBS-Tween) followed by an 1 hour 17 
incubation of the membranes in the primary antibody (anti-LRP/LR specific antibody IgG1-18 
iS18) diluted 1:5000 in blocking buffer. Three washes in washing buffer (10 min each) were 19 
performed before incubation of the membranes in secondary antibody (anti-human IgG-HRP 20 
conjugated antibody) diluted 1:10000 in blocking buffer for 1 hour. Three washes were again 21 
performed as previously mentioned before chemiluminescent substrate was added for detection 22 
of proteins. X-ray films were used to capture the chemiluminescent reaction. β-actin (mouse 23 
 6 
monoclonal anti-β-actin peroxidase; Sigma) served as a loading control. Densitometry was 1 
performed to quantify protein levels with ImageJ™ software. 2 
MTT assay. Both AsPC-1 and IMR-32 cells were seeded at a density of 1x104 cells per well in a 3 
24-well plate and transfected 24 hours later.  Seventy two hours post transfection, 100µg of MTT 4 
was added to each well, and incubated for 2 hours at 37°C. Post incubation, the MTT-containing 5 
medium was discarded from each well and the remaining formazan crystals were dissolved in 6 
500µl of DMSO. The absorbance was measured at 570nm using an ELISA plate reader. Controls 7 
included untreated cells, negative control siRNA treated cells, and positive control 8 
protocatechuic acid (PCA) treated cells. 9 
BrdU assay. BrdU assays were performed using a BrdU Cell Proliferation Kit (Calbiochem) 10 
according to the manufacturer’s instructions. In brief, cells were seeded at a density of 1 x 104 11 
cells in a 24-well plate and transfected. Post transfection (72 hours), 80μl of a working stock of 12 
BrdU was added to each well followed by a 24 hour incubation period at 37°C. Following 13 
aspiration of contents, 800μl of fixative solution was added to each well and incubated for 30min 14 
at room temperature. After removal of the fixative, cells were subjected to an hour incubation in 15 
100μl of anti-BrdU antibody. Cells were washed thrice with wash buffer and incubated for 16 
30min, at room temperature, with 400µl of the peroxidase anti-mouse IgG HRP-conjugated 17 
antibody. After cells were washed three times, 400μl of substrate solution was added followed by 18 
a subsequent incubation period of 15min. Absorbance was measured within 30min of addition of 19 
stop solution (400μl) at dual wavelengths of 450 and540 nm. Untreated cells were used as a 20 
control and siRNA-scr and PCA were used as negative and positive controls, respectively. 21 
Confocal microscopy. AsPC-1 and IMR-32 cells were seeded onto coverslips at a density of 22 
1x104 cells prior to siRNA transfection. Thereafter, 72 hours post transfection, cells were fixed in 23 
 7 
4% paraformaldehyde for 15 min followed by three washes with PBS. Post washing, cells were 1 
incubated with Hoechst 33342 nuclear stain diluted in PBS (1:100) for 5 to 10 min in the dark. 2 
The coverslips were then washed 2-3 times in PBS and thereafter, coverslips were mounted (cell 3 
side down) onto a clean microscope slide using mounting fluid. After setting for 45 min in the 4 
dark, slides were stored at 4ºC until ready to view with a confocal microscope (Zeiss LSM 780). 5 
Controls included untreated cells, cells treated with siRNA-scr (negative control) and PCA 6 
(positive control). 7 
Annexin V-FITC/7AAD assays. The Annexin V-FITC/7-AAD assay (Beckman Coulter) was 8 
performed according to the manufacturer’s instructions. Briefly, post siRNA transfection, cells 9 
were harvested with trypsin/EDTA and washed with cold PBS by centrifugation at 500 x g for 5 10 
min. The cells were resuspended in 1 x Annexin-binding buffer and 10µl of Annexin V-FITC 11 
solution and 20µl of 7-AAD viability dye was added to 100µl of the cell suspensions. The cell 12 
suspensions were then incubated on ice for 15 min in the dark. Finally, samples were 13 
supplemented with 400μl of cold 1X Annexin binding buffer prior to flow cytometric analysis. 14 
Untreated cells, siRNA-scr treated cells, and PCA treated cells were used as controls. Samples 15 
were analysed using the BD Accuri C6 flow cytometer, where the FL-1 laser was used to detect 16 
Annexin V- FITC staining and FL-3 was used for detection of 7-AAD staining. Compensation 17 
and quadrants were set using the following controls: unstained cells, Annexin V-FITC stained 18 
cells, 7-AAD stained cells, cells stained with both Annexin V-FITC and 7-AAD, and PCA-19 
treated cells stained with both Annexin V-FITC and 7-AAD. 20 
Caspase-3, -8 and -9 activity assays. Caspase 3, Caspase 8 and Caspase 9 Activation Assays 21 
(Abcam) were performed according to manufacturer’s instructions. In brief, 72 hours after 22 
siRNA transfection, 1x106 cells were pelleted by centrifugation at 1200 rpm for 10 min. 23 
 8 
Thereafter, cells were re-suspended in 50µl of cell lysis buffer and incubated on ice for 10 min. 1 
This was followed by centrifugation of cells at 10000 x g for 1 min. Following this, the protein 2 
concentration of the supernatant was determined by use of a BCATM assay and subsequently, 3 
200µg of protein was diluted to 50µl with cell lysis buffer and added to appropriate wells of a 4 
96-well plate. The 2X reaction buffer was then supplemented with DTT (10µl DTT/1ml reaction 5 
buffer) and 50µl of this solution was added to each sample, followed by the addition of 5µl of 6 
peptide substrate. After a 2 hour incubation period at 37ºC, the absorbance was measured at 7 
405nm using an ELISA plate reader. In addition to untreated cells, siRNA-scr treated and PCA 8 
treated cells were used as negative and positive controls, respectively. 9 
Statistical evaluation. The two-tailed Student’s t-test with a confidence interval of 95% was 10 
used in order to analyse the data, with p-values of less than 0.05 being considered as significant. 11 
This statistical analysis was done using Graphpad Prism version 5.03.  12 
  13 
 9 
Results 1 
siRNA technology leads to down-regulation of LRP expression in pancreatic cancer and 2 
neuroblastoma cells. In order to determine the effect of LRP/LR expression on cellular 3 
viability, siRNA-mediated knockdown of LRP/LR was performed. Post transfection of 4 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells with siRNA-LAMR1 5 
(specifically targeting the mRNA of the 37kDa LRP), Western blot analysis and subsequent 6 
densitometry was performed. Densitometric analysis revealed that LRP was successfully down-7 
regulated in both AsPC-1 (Fig.1a and 1b) and IMR-32 (Fig.1c and 1d) cells by transfection with 8 
the afore-mentioned siRNA. It was observed that siRNA-LAMR1 transfected AsPC-1 and IMR-9 
32 cells exhibited a 90% and 71% reduction in LRP expression, respectively, when compared to 10 
non-transfected cells, set to 100%. Moreover, transfection of AsPC-1 cells with siRNA-scr 11 
(negative control scrambled siRNA) showed no significant LRP knockdown when compared to 12 
non-transfected cells (Fig.S1a and S1b). Likewise, the same effect was observed when IMR-32 13 
cells were transfected with siRNA-scr (Fig.S1c and S1d). 14 
siRNA-mediated down-regulation of LRP expression results in significantly reduced 15 
viability of pancreatic cancer and neuroblastoma cells. After siRNA-mediated knockdown of 16 
LRP, the effect thereof on cellular viability was analysed. Following treatment of AsPC-1 and 17 
IMR-32 cells with siRNA-LAMR1, MTT assays revealed that cellular viability was significantly 18 
reduced in comparison to controls. This signifies that siRNA-mediated LRP knockdown leads to 19 
the observed decreases in cellular viability in both of the tumourigenic cell lines.  20 
It was seen that AsPC-1 and IMR-32 cells treated with siRNA-LAMR1 exhibited an 82% and 21 
75% reduction in cellular viability, respectively, when compared to non-transfected cells 22 
(Fig.1e). Moreover, no significant reduction in cellular viability was observed for both cell lines 23 
 10 
when treated with the negative control siRNA-scr and compared to non-transfected cells 1 
(Fig.1e). Protocatechuic acid (PCA) was used as a positive control treatment as it is a known 2 
apoptosis inducer. 3 
Use of an alternative siRNA confirms that LRP down-regulation is responsible for 4 
reductions in cellular viability in pancreatic cancer and neuroblastoma cells. In order to 5 
ascertain whether the observed reduction in cellular viability occurred as a result of siRNA-6 
LAMR1-mediated LRP down-regulation and not an off-target effect, an additional siRNA 7 
targeting a different region of LRP was used.  After transfection of cells with the alternative 8 
siRNA (esiRNA-RPSA), Western blot analysis and densitometry was performed. By comparison 9 
to non-transfected cells, pancreatic cancer (AsPC-1) cells showed a significant knockdown of 10 
83% in LRP expression (Fig.2a and 2b). Similarly, neuroblastoma (IMR-32) cells exhibited a 11 
significant down-regulation of 64% in LRP expression when compared to non-transfected cells 12 
(Fig.2c and 2d). Additionally, treatment of AsPC-1 cells with esiRNA-RLUC (negative control 13 
siRNA) displayed no significant difference in LRP expression when compared to non-transfected 14 
cells (Fig.S2a and S2b). Likewise, the same effect was observed for IMR-32 cells treated with 15 
esiRNA-RLUC (Fig.S2c and S2d).  16 
To assess the effects of esiRNA-RPSA-mediated LRP knockdown on the viability of AsPC-1 17 
and IMR-32 cells, MTT assays were performed. It was found that treatment of cells with this 18 
alternative siRNA resulted in significantly reduced cellular viability in both tumourigenic cell 19 
lines under study. Specifically, AsPC-1 cells showed an 82% reduction in cellular viability post 20 
siRNA treatment whilst IMR-32 cells exhibited a 60% reduction when compared to non-21 
transfected cells (Fig.2e). Moreover, treatment of both cell lines with the negative control siRNA 22 
 11 
(esiRNA-RLUC) did not result in a significant change in cellular viability when compared to 1 
non-transfected cells (Fig.2e).  2 
Knockdown of LRP expression by siRNA significantly reduces cell proliferation. Due to the 3 
observed reduction in cellular viability of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-4 
32) cells upon treatment with siRNA, the effect of siRNA-mediated down-regulation of LRP 5 
expression on cellular proliferation was also investigated since a loss in cellular viability could 6 
be a result of reduced proliferation rates. Cellular proliferation was analysed by use of the BrdU 7 
assay.  8 
It was observed that AsPC-1 and IMR-32 cells showed significant reductions of 76% and 44% in 9 
cellular proliferation, respectively, after being treated with siRNA-LAMR1 and compared to 10 
non-transfected cells (Fig.3). Furthermore, treatment of both cell lines with the negative control 11 
siRNA (siRNA-scr) showed no significant differences in cellular proliferation when compared to 12 
non-transfected cells (Fig.3).  13 
siRNA-mediated knockdown of LRP expression results in nuclear morphological changes 14 
indicating apoptotic induction. To examine if apoptotic induction led to the reductions in 15 
cellular viability post siRNA-LAMR1 treatment, nuclear morphology was investigated by 16 
confocal microscopy. Compared to the nuclei of non-transfected cells (Fig.4a), siRNA-LAMR1 17 
treated pancreatic cancer cells (AsPC-1) displayed nuclear morphology indicative of apoptosis 18 
(Fig.4d). Similarly, comparison of nuclei of siRNA-LAMR1 treated neuroblastoma cells (IMR-19 
32) (Fig.4h) to the nuclei of non-transfected cells (Fig.4e) revealed nuclear morphological 20 
changes such as nuclear shrinkage, membrane blebbing and the formation of apoptotic bodies. 21 
Moreover, treatment of both cell lines with the negative control siRNA-scr did not result in 22 
changes in nuclear morphology when compared to non-transfected cells (Fig.4b and 4f). PCA 23 
 12 
was used as a positive control for studying nuclear morphological changes under apoptotic 1 
conditions (Fig.4c and 4g). 2 
siRNA-mediated down-regulation of LRP expression leads to phosphatidylserine 3 
externalization and apoptotic induction. Confocal microscopy suggested that knockdown of 4 
LRP expression in pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells causes nuclear 5 
morphological changes that are characteristic of cells undergoing apoptosis. In order to confirm 6 
that this observation of apoptotic induction holds true for both the cell lines in question, an 7 
Annexin V-FITC/ 7-AAD assay was performed. 8 
It was observed that transfection of AsPC-1 cells with siRNA-LAMR1 resulted in 76% of cells 9 
undergoing apoptosis (Fig.5d) when compared to non-transfected cells (Fig5a). Treatment of 10 
IMR-32 cells with siRNA-LAMR1 induced apoptosis in 42.7% of cells (Fig.5h) when compared 11 
to non-transfected cells (Fig.5e). Furthermore, treatment of both cell lines with the negative 12 
control siRNA-scr did not induce apoptosis (Fig.5b and 5f). Protocatechuic acid (PCA) was used 13 
as a positive control (Fig.5c and 5g).  14 
siRNA-mediated knockdown of LRP expression leads to significantly increased caspase-3 15 
activity. To further confirm that down-regulation of LRP induces apoptosis in pancreatic cancer 16 
(AsPC-1) and neuroblastoma (IMR-32) cells, caspase-3 activity was assessed. It was found that 17 
after transfection with siRNA-LAMR1, AsPC-1 cells displayed a significant 10-fold increase in 18 
caspase-3 activity when compared to non-transfected cells (Fig.6a). IMR-32 cells showed a 6-19 
fold increase in caspase-3 activity after treatment of cells with siRNA-LAMR1 and compared to 20 
non-transfected cells (Fig.6a). Additionally, treatment of both cell lines with the negative control 21 
siRNA-scr showed no significant differences in caspase-3 activity when compared to non-22 
transfected cells (Fig.6a). 23 
 13 
Pancreatic cancer and neuroblastoma cells exhibit significantly increased caspase-8 activity 1 
after siRNA-mediated down-regulation of LRP expression. Since caspase 3 is activated in 2 
both the intrinsic and extrinsic pathways of apoptosis, caspase-8 activity assays were performed 3 
to further understand the role LRP/LR plays in promoting cell survival of cancerous cells. This 4 
assay was used to gain further insight into whether transfection with siRNA-LAMR1 results in 5 
activation of the caspase-8-mediated extrinsic pathway in both cell lines. It was observed that 6 
AsPC-1 and IMR-32 cells treated with siRNA-LAMR1 experienced a significant 3-fold and 4-7 
fold increase in caspase-8 activity, respectively, when compared to non-transfected cells 8 
(Fig.6b). Moreover, transfection of both cell lines with the negative control siRNA-scr revealed 9 
no significant differences in caspase-8 activity when compared to non-transfected cells (Fig.6b).  10 
Pancreatic cancer cells show a significant increase in caspase-9 activity after siRNA-11 
mediated LRP knockdown. Caspase-9 activity assays were used to establish whether pancreatic 12 
cancer (AsPC-1) and neuroblastoma (IMR-32) cells undergo apoptosis through the caspase-9-13 
mediated intrinsic pathway after siRNA-mediated LRP downregulation. It was found that AsPC-14 
1 cells exhibited a significant 3-fold increase in caspase-9 activity after transfection with siRNA-15 
LAMR1, when compared to non-transfected cells (Fig.6c). No significant difference was 16 
however observed in caspase-9 activity in IMR-32 cells after transfection when compared to 17 
non-transfected cells (Fig.6c). Furthermore, treatment of both cell lines with the negative control 18 
siRNA-scr resulted in no significant differences in caspase-9 activity when compared to non-19 





The overexpression of LRP/LR in cancerous cell lines and its involvement in numerous 2 
tumourigenic processes has made this receptor an attractive target for study. Specifically, tumour 3 
progression is enhanced by the LRP/LR-assisted promotion of processes such as tumour 4 
angiogenesis, metastasis and apoptotic evasion – three out of the six hallmarks of cancer[35]. The 5 
widespread cellular localization of LRP/LR allows this receptor to serve several physiological 6 
functions such as cell adhesion, cell migration and proliferation, cell viability, regulation of the 7 
cell cycle, protein synthesis and ribosomal RNA processing. Due to LRP/LR over-expression, 8 
these functions may be exploited in tumour cells, leading to the occurrence of the afore-9 
mentioned tumour-promoting processes. 10 
In order to determine the role played by LRP/LR in the maintenance of cellular viability, siRNAs 11 
were used to downregulate LRP expression in AsPC-1 and IMR-32 cells (Fig.1 and 2) and the 12 
effect on cell viability was assessed. Treatment of the cells with siRNA-LAMR1 and esiRNA-13 
RPSA resulted in significant reductions in viability which correlated with siRNA-mediated LRP 14 
knockdown expression levels (Fig. 1e and 2e). This observation suggests that LRP plays a 15 
crucial role in cell survival of these two cancer cell lines.  16 
Since it is known that, in addition to viability, LRP/LR plays a role in proliferation, we wanted to 17 
establish whether downregulation of LRP/LR would further impair cellular division of AsPC-1 18 
and IMR-32 cells. After transfection with siRNA-LAMR1, AsPC-1 and IMR-32 cells showed 19 
reductions in cellular proliferation that correlated with the LRP expression levels observed after 20 
downregulation. This suggests that LRP/LR plays a role in cellular division which might in 21 
addition facilitate cellular viability maintenance. LRP/LR has also been identified in interactions 22 
with certain proteins that govern cell cycle progression, such as cyclins A2 and B1, CDK’s 1 and 23 
 15 
2, and p2  [11], thus providing not only an explanation for the hampered cellular growth but also 1 
the decreased proliferation observed upon siRNA treatment.  2 
Next we wanted to determine whether apoptosis was the form of cell death responsible for the 3 
observed reduction in the viability of AsPC-1 and IMR-32 cells after LRP downregulation. After 4 
treatment of these two cell lines with siRNA-LAMR1, confocal microscopy revealed evident 5 
alterations in nuclear morphology – such as nuclear shrinkage, nuclear membrane blebbing and 6 
the formation of apoptotic bodies (Fig.4). Due to the maintenance of nuclear structures by the 7 
binding of nuclear and perinuclear LRP/LR to histones[36], it is clear that knockdown of this 8 
receptor leads to diminished nuclear integrity and altered nuclear morphology. These siRNA-9 
LAMR1-induced changes to the nuclear morphology of AsPC-1 and IMR-32 are indicative of 10 
apoptotic induction in these cell lines. 11 
Further confirmation and quantification of apoptotic induction was achieved by use of an 12 
Annexin-V-FITC/ 7-AAD assay. It was observed that non-transfected and negative control 13 
siRNA-scr transfected AsPC-1 and IMR-32 cells did not display Annexin-V and/or PI, which is 14 
representative of live cells. However, 8mM PCA-treated and siRNA-LAMR1-treated AsPC-1 15 
and IMR-32 cells exhibited an increase in Annexin-V or Annexin-V and PI which is indicative 16 
of early and late stage apoptosis respectively. The shift from negative to positive Annexin-V 17 
staining signifies that siRNA-LAMR1-mediated LRP down-regulation in AsPC-1 and IMR-32 18 
cells triggers loss of membrane asymmetry and PS externalization on the outer leaflet of the 19 
plasma membrane which are common features of apoptotic cells [37]. 20 
Nuclear morphological studies as well as Annexin V assays proved that siRNA-mediated 21 
knockdown of LRP expression leads to apoptotic induction in AsPC- 1 and IMR-32 cells. 22 
Additionally, caspase-3 assays were performed in order to further ascertain the occurrence of 23 
 16 
apoptotic induction as well as the involvement of caspases after treatment of these cell lines with 1 
siRNA-LAMR1. Caspase-3 is an effector caspase that exhibits increased activity in cells that are 2 
actively undergoing apoptosis. After treatment of AsPC-1 and IMR-32 cells with siRNA-3 
LAMR1, there was a marked increase in caspase-3 activity in both cell lines when compared to 4 
non-transfected cells. These findings clearly indicate that siRNA-mediated LRP down-regulation 5 
induces apoptosis in these two tumourigenic cell lines. This observation of apoptotic induction 6 
after siRNA-mediated LRP knockdown may also be attributed to the interaction of LRP/LR with 7 
focal adhesion kinase (FAK). A recent study showed that after LRP/LR binds to laminin, 8 
interactions can occur between LRP/LR and FAK[38]. These interactions were implicated in the 9 
activation of PI3-kinase/AKT and MEK/ERK 1/2 cell survival pathways and also the up-10 
regulation of Bcl-2 - an anti-apoptotic protein[38]. Alternatively, down-regulation of LRP by 11 
siRNAs may have led to apoptotic induction due to the ribosomal functions of LRP/LR. It is 12 
known that LRP/LR plays a role in the biogenesis of ribosomes by facilitating 21S pre-rRNA 13 
processing into mature 18S rRNA[13], and also associates with and acts as a component of the 14 
40S ribosomal small subunit where it assists with protein translation and synthesis[39-41]. 15 
Therefore, knockdown of LRP in this study might interfere with ribosome formation and 16 
consequent translation of proteins that are critically involved in proper cell functioning and 17 
survival, thereby leading to cell death.   18 
As mentioned before LRP/LR plays a role in the PI3-kinase/AKT and MEK/ERK 1/2 cell 19 
survival pathways. Since both these pathways are involved in inhibiting the intrinsic as well as 20 
extrinsic apoptotic pathways, caspase-8 and caspase-9 assays were performed to assess which 21 
apoptotic pathway is induced after siRNA-LAMR1-mediated knockdown of LRP/LR. It was 22 
observed that both of the tumourigenic cell lines exhibited increased caspase-8 activity after 23 
 17 
treatment with siRNA-LAMR1, when compared to non-transfected cells indicating that the 1 
extrinsic apoptotic pathway is activated [42].  2 
In addition, it was observed that AsPC-1 cells treated with siRNA-LAMR1 exhibited a 3 
significant increase in caspase-9 activity in comparison to non-transfected cells. Caspase-9 is 4 
intricately involved in the mitochondrial (intrinsic) pathway[42], thus suggesting that siRNA-5 
mediated LRP knockdown also induces apoptosis in AsPC-1 cells via the intrinsic pathway.  6 
Interestingly, it has been shown by Celay et al. [43]that activation of the apoptotic intrinsic 7 
pathway is less probable after treatment of IMR-32 cells with 9-cis Retinoic Acid (RA).  8 
Treatment of IMR-32 and SH-SY5Y cells with 9-cis RA leads to an increase of BIRC3 and 9 
BIRC8 (an inhibitor of APAF1, BAX and Caspase 9) and to a decrease of APAF1 and BCL10 10 
(an activator of Caspase 9), respectively, suggesting a lesser formation of the apoptosome and a 11 
blockade of the intrinsic pathway.  Moreover,  RA causes downregulation of the 67 kDa Laminin 12 
Receptor which correlates with reduced biological aggressiveness of human neuroblastoma 13 
cells[44]. We therefore suggest that the decrease in caspase 9 activation observed after treatment 14 
of RA is possibly due to the downregulation of the 67 kDa Laminin Receptor. This might explain 15 
why siRNA mediated downregulation of LRP induces caspase 8 activation in both cell lines 16 
whilst caspase 9 activation occurs only in AsPC-1 cells.  17 
Besides its normal roles in mediating cell viability, cellular adhesion and functioning as a 18 
member of the ribosomal translational machinery, LRP/LR has been implicated in a number of 19 
pathological processes including cancer and metastasis [45].  However, the induction of apoptosis 20 
in response to downregulation of  LRP/LR, as shown here and previously for MCF-7, MDA-21 
MB231and WHCO1 cells [32], suggests that this may not be a practical approach without specific 22 
targeting to avoid inducing apoptosis in non-tumourigenic cells. Interestingly, though, we have 23 
 18 
previously shown that shRNA mediated downregulation of LRP/LR had no significant effect on 1 
the viability of non-cancerous HEK293 cells suggesting that this protein might be crucial for cell 2 
survival in certain cell types only[17]. As such, modifying the expression of LRP/LR is an 3 
attractive therapeutic target for the treatment of cancer.  4 
 5 
Conclusion 6 
The present study has demonstrated that the siRNA-mediated knockdown of LRP expression 7 
significantly reduced the viability of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) 8 
cells through hampering of cell proliferation and through the induction of apoptosis. In IMR-32 9 
cells, apoptosis was solely induced through the death receptor (extrinsic) pathway while 10 
apoptosis occurred via both the intrinsic and extrinsic pathways in AsPC-1 cells. It is likely that 11 
the PI3K/AKT and MAPK/ERK pathways are involved however the exact mechanism of action 12 
warrants further investigation. These findings exemplify the critical role played by LRP/LR in 13 
the maintenance of cellular viability in both of these tumourigenic cell lines. Furthermore, this in 14 
vitro study highlights the potential of using siRNAs targeting LRP therapeutic tools for the 15 
treatment of pancreatic cancer and neuroblastoma. Future research will therefore include 16 
investigation of the effect of LRP/LR knock-down strategies in in vivo cancer models. 17 
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Figure Legends 1 
Figure 1: LRP expression in pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells 2 
after siRNA transfection, and the subsequent effect of siRNA-mediated LRP 3 
downregulation on cellular viability. a) and b) Transfection of AsPC-1 cells with siRNA-4 
LAMR1 resulted in significant 90%  knockdown of  LRP when compared to non-transfected 5 
cells. The value for the non-transfected cells was set to 100%. **p=0.0086.  c) and d) 6 
Densitometry revealed that there was a significant 71% reduction of LRP expression after 7 
transfection of IMR-32 cells with siRNA-LAMR1 when compared to non-transfected cells. The 8 
value for non-transfected cells was set to 100%. *p=0.0117. e)  MTT assays were used to analyse 9 
the viability of AsPC-1 and IMR-32 cells after treatment with siRNA-LAMR1. The value for 10 
non-transfected cells was set to 100% for both cell lines and by comparison, AsPC-1 and IMR-11 
32 cells treated with siRNA-LAMR1 displayed a significant reduction of 82% and 65% in 12 
cellular viability, respectively. Cells treated with the negative control siRNA-scr showed no 13 
significant differences in cellular viability when compared to non-transfected cells for both cell 14 
lines. Protocatechuic acid (PCA) was used as a positive control. Graph is representative (mean ± 15 
STD) of an average of experiments performed in triplicate and repeated three times. **p=0.0017, 16 
***p=0.0008, N.S.: p>0.05, non-significant. 17 
Figure 2: Detection of LRP expression in pancreatic cancer (AsPC-1) and neuroblastoma 18 
(IMR-32) cells after transfection with esiRNA-RPSA, and the subsequent effect thereof on 19 
cellular viability. a) and b) After transfection of AsPC-1 cells with esiRNA-RPSA, there was a 20 
significant reduction of 83% in LRP expression when compared to non-transfected cells. β-actin 21 
was used as a loading control. **p=0.0057.  c) and d) Densitometry revealed that after treatment 22 
of IMR-32 cells with esiRNA-RPSA, there was a significant reduction of 64% in LRP 23 
 24 
expression when compared to non-transfected cells. Non-transfected cells were set to 100% to 1 
allow for comparison and β-actin was used as a loading control. *p=0.025. e) After 2 
downregulation of LRP with esiRNA-RPSA, MTT assays were performed to assess cellular 3 
viability. Compared to non-transfected cells (set to 100%), AsPC-1 and IMR-32 cells showed a 4 
reduction of 82% and 60% in cellular viability, respectively. No significant differences were 5 
observed in the viability of cells treated with the negative control siRNA (esiRNA-RLUC) when 6 
compared to non-transfected cells for both cell lines. PCA was used as a positive control. Data 7 
shown are representative (mean ± STD) of three biological replicates, each performed in 8 
triplicate. **p=0.0014, ***p=0.0005, N.S.: p>0.05 therefore non-significant. 9 
Figure 3: The effect of siRNA-mediated LRP knockdown on the proliferation of pancreatic 10 
cancer (AsPC-1) and neuroblastoma (IMR-32) cells. After downregulation of LRP, AsPC-1 11 
cells showed a 76% reduction in cellular proliferation when compared to non-transfected cells 12 
(set to 100%). IMR-32 cells showed a decrease of 44% in proliferation after siRNA-LAMR1 13 
treatment by comparison to non-transfected cells. Treatment of both cell lines with the negative 14 
control siRNA-scr revealed no significant changes in cellular proliferation when compared to 15 
non-transfected cells. Protocatechuic acid was used as a positive control and data shown are 16 
representative (mean ± STD) of three biological replicates, each performed in triplicate. 17 
**p=0.0053 and 0.0031 for AsPC-1 and IMR32 cells, respectively. N.S.: p>0.05, non-18 
significant. 19 
Figure 4: The effect of siRNA-mediated LRP knockdown on nuclear morphology of 20 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. a) Non-transfected AsPC-1 21 
cells showed normal rounded nuclei with uncompromised integrity. b) AsPC-1 cells treated with 22 
the negative control siRNA-scr displayed nuclei similar to that of the non-transfected cells. c) 23 
 25 
PCA-treated AsPC-1 cells showed membrane blebbing and apoptotic body formation (indicated 1 
by white arrows). d) siRNA-LAMR1 transfected AsPC-1cells exhibited diminished nuclear 2 
integrity and the formation of apoptotic bodies (shown by white arrows).  e) Nuclear integrity is 3 
maintained in non-transfected cells, evident by the normal rounded shape of nuclei of the IMR-4 
32 cells. f) Negative control siRNA-scr transfected IMR-32 cells showed normal rounded nuclei 5 
with uncompromised integrity. g) PCA (positive control) treated IMR-32 cells showed nuclear 6 
shrinkage (indicated by white arrows). h) siRNA-LAMR1 transfected IMR-32 cells showed 7 
compromised nuclear integrity, made clear by the observation of nuclear shrinkage and apoptotic 8 
body formation (shown by white arrows). All images were obtained at a magnification of 63X. 9 
Scale bar applies to all images. 10 
Figure 5: Apoptotic induction in pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) 11 
cells after siRNA transfection. a) and e) Non-transfected cells show that majority of cells lie in 12 
the lower left quadrant (Q1-LL) which is indicative of normal living cells. b) and f) Treatment of 13 
cells with the negative control siRNA-scr also resulted in majority of the cells appearing in the 14 
lower left quadrant. c) and g) Protocatechuic acid (PCA) was used as a positive control and 15 
resulted in most of the cells appearing in the upper right quadrant (Q1-UR), which is 16 
representative of cells undergoing late apoptosis. d) and h) Transfection of cells with siRNA-17 
LAMR1 led to 0.8% of AsPC-1cells and 7.5% of IMR-32 cells undergoing early apoptosis, as 18 
shown in the lower right quadrant (Q1-LR), and 75.2% of AsPC-1cells and 35.2% of IMR-32 19 
cells undergoing late apoptosis – therefore a total of 76% of AsPC-1 and 42.7% of IMR-32 cells 20 
underwent apoptosis after siRNA-LAMR1 treatment. Plots are indicative of an average of 21 
experiments performed in triplicate and repeated three times. 22 
 26 
Figure 6: The effect of siRNA-mediated LRP down-regulation on caspase-3, -8 and -9 1 
activity in pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells.  a) Caspase-3 2 
activity assays showed that after treatment of cells with siRNA-LAMR1, AsPC-1 and IMR-32 3 
cells showed a significant 10-fold and 6-fold increase in caspase-3 activity, respectively, when 4 
compared to non-transfected cells (which were set to 100%). No significant difference was 5 
observed when both cell lines were treated with the negative control siRNA-scr and compared to 6 
non-transfected cells. Prototechuic acid (PCA) was used as a positive control. *p=0.0109 and 7 
0.0154 for AsPC-1 and IMR-32, respectively. N.S: p>0.05, non-significant. b) siRNA-LAMR1 8 
transfected AsPC-1 and IMR-32 cells showed a significant 3-fold and 4-fold increase in caspase-9 
8 activity, respectively, when compared to non-transfected cells (set to 100%). Treatment of both 10 
cell lines with the negative control siRNA-scr resulted in no significant difference in caspase-8 11 
activity when compared to non-transfected cells.  *p=0.0357, **p=0.0053, N.S: p>0.05, non-12 
significant. c) siRNA-LAMR1 transfected AsPC-1 cells showed a significant 3-fold increase in 13 
caspase-9 activity when compared to non-transfected cells (set to 100%). Treatment of IMR-32 14 
cells with siRNA-LAMR1 showed no difference in caspase-9 activity by comparison to non-15 
transfected cells. Both tumourigenic cell lines displayed no significant difference in caspase-9 16 
activity after treatment with the negative control siRNA-scr when compared to non-transfected 17 
cells. **p=0.0016, N.S.: p>0.05, non-significant.  Data shown are representative (mean ± STD) 18 
of three biological replicates, each performed in triplicate. 19 
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